Drugs that contain Daptomycin

1. Drug name - CUBICIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8003673 CUBIST PHARMS LLC Daptomycin for the treatment of biofilm and catheter salvage Sep, 2028

(5 years from now)

US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods Nov, 2030

(8 years from now)

Treatment: Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
250MG/VIAL POWDER;INTRAVENOUS Discontinued
500MG/VIAL POWDER;INTRAVENOUS Prescription

2. Drug name - DAPTOMYCIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357535 HOSPIRA INC Daptomycin formulations and uses thereof Sep, 2033

(10 years from now)

US9655946 HOSPIRA INC Daptomycin formulations and uses thereof Sep, 2033

(10 years from now)

Treatment: Treatment of complicated skin and skin structure infections and s. aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by reconstituting and administering the formulation as recited in claim 12; Treatment of complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis by administering the formulation of daptomycin as recited in claim 18

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
350MG/VIAL POWDER;INTRAVENOUS Prescription
500MG/VIAL POWDER;INTRAVENOUS Prescription

3. Drug name - DAPZURA RT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11173189 BAXTER HLTHCARE CORP Daptomycin formulations containing a combination of sorbitol and mannitol Mar, 2041

(18 years from now)

Treatment: Method of treating a bacterial infection by administering a reconstituted solid formulation of daptomycin containing 31.0 to 59.4% wt total mannitol and sorbitol

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.